BioMarin Pharma (BMRN) Q2 Revenues Miss; Reaffirms FY Revs
Tweet Send to a Friend
BioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), which may ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
